Clinical Trial Update: Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD [Phase 2]

View source ↗

Summary

Phase 2 trial in acute myeloid leukemia with measurable residual disease reports discontinuation of a hypomethylating agent and venetoclax; the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Hypomethylating agent
• Venclexta (venetoclax)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING